# Kiora Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kiora-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.kiorapharma.com
- Total disclosed funding: $34M
- Latest round: Series D (Dec 8, 2009)
- Investors on record: 5

## About

Based in Massachusetts, US, and founded in 1998 by Franz Obermayr (CEO), and VP Brenda Mann, Eyegate Pharmaceuticals Inc doing business as Kiora Pharmaceuticals, Inc. operates as a pharmaceutical company that develops medicine to treat eye diseases. In January 2021, Eyegate Pharmaceuticals Inc raised USD 8 million in venture funding from new investor Armistice Capital.

Kiora Pharmaceuticals, Inc. develops EGP-437 a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through a drug delivery system, the EyeGate II Delivery System. It develops EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and ciliary body.

Eyegate Pharmaceuticals Inc plans to expand its operations such as clinical trials, working capital, and other general corporate purposes.

## Funding rounds

- Series D, Dec 8, 2009, $11M — Ventech, Ostrum Private Equity, IPSA, Medicis Capital
- Series C, Mar 12, 2008, $9M — Ventech, Nexus Group, IPSA, Medicis Capital
- Series B, Jan 17, 2007, $4M — Nexus Group
- Series B, Nov 2, 2006, $10M — Ventech, IPSA

## Investors

- Ventech (https://capitalatlas.ai/funds/ventech) — Series B, Series C, Series D
- IPSA (https://capitalatlas.ai/funds/ipsa) — Series B, Series C, Series D
- Nexus Group (https://capitalatlas.ai/funds/nexus-group) — Series B, Series C
- Medicis Capital — Series C, Series D
- Ostrum Private Equity (https://capitalatlas.ai/funds/ostrum-private-equity) — Series D